Pharmaceutical sponsor
Chong Kun Dang Pharmaceutical Clinical Trials
Studies where Chong Kun Dang Pharmaceutical is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 11Diabetes Mellitus, Type 2
Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
- Trial name
- TRIO (NCT06838286)
- Testing
- SGLT2 inhibitor, Thiazolidinedione, DPP-4 inhibitor
- Where
- South Korea
- Volunteers
- 10,000 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Androgenetic Alopecia
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
- Trial name
- NCT06916793
- Testing
- CKD-843 dose#1, CKD-843 dose#2, Dutasteride Capsules
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetics and safety of CKD-339 in healthy volunteers.
- Trial name
- NCT07748702
- Testing
- CKD-339, D311, D107
- Where
- South Korea
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
This is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung…
- Trial name
- NCT07439094
- Testing
- CKD-703
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Ovarian Cancer
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215
- Trial name
- NCT07532148
- Testing
- CKD-215, D215
- Volunteers
- 24 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Advanced Solid Tumors, Metastatic Solid Tumors
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
The purpose of this first-in-human (FiH) study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CKD-512 given alone and in combination with pembrolizumab in subjects…
- Trial name
- NCT07215637
- Testing
- CKD-512, Pembrolizumab
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabete Type 2
Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
- Trial name
- EMPAGO (NCT07365358)
- Testing
- empagliflozin 10mg, Glimepiride 1mg
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Atopic Dermatitis
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
This is a randomised, double-blind, three-arm, parallel group, single-dose, Phase 1 comparative study of CKD-706, US-Dupixent, and EU-Dupixent in healthy adult participants.
- Trial name
- CKD-706 (NCT07358156)
- Testing
- CKD-706, US-Dupixent, EU-Dupixent
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 519 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Psoriasis
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi…
- Trial name
- NCT07258745
- Testing
- SKYRIZI, CKD-704
- Where
- Poland
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
- Trial name
- NCT06643819
- Testing
- Sacubitril∙Valsartan(dose maintenance), Sacubitril∙Valsartan(dose increasing), Valsartan
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Completed, with results posted
All 1Aspergillus Infections, Candida Infections
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
- Conditions
- Aspergillus Infections, Candida Infections, Fungal Infections
- Trial name
- NCT02631954
- Testing
- Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical